Rising Neurological Diseases, and Funding Provided by Key Manufacturers to Boost the Market Growth

Published: Apr 2023

The global neurological biomarkers market is anticipated to grow at a CAGR of 12.4% during the forecast period (2023-2030). Neurological biomarkers assist in monitoring the progress of neurological disease and studying biological responses toward a treatment. Neurological biomarkers capture different characteristics of a disease such as pathogenicity and heterogeneity, which helps in the development of personalized treatment therapy. Rapid research, technological advances, and funding in the field of neurology have led to the introduction of novel biomarkers that are accurate, reliable, and sensitive. For instance, in 2022, Johns Hopkins University (Baltimore, Maryland), Howard Lederman, granted funding of $1.6 million over four years. Moreover, in 2022, Virginia Commonwealth University provided funding of $1.6 million for type-1 to establish biomarkers and clinical endpoints.  

Browse the full report description of “Neurological Biomarkers Market Size, Share & Trends Analysis Report by Biomarker Type (Imaging Biomarkers, Metabolomics Biomarkers, Proteomic Biomarkers, and Genomics Biomarkers), by Application (Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Autism Spectrum Disorders, and Others), and by End Users (Hospital, Clinical Diagnostic Centers, Research Organizations) Forecast Period (2023-2030)” at https://www.omrglobal.com/industry-reports/neurological-biomarkers-market

In addition, key players such as C?N’s Diagnostics, Neurosteer Ltd., Proteome Sciences PLC, and others are adopting numerous strategies such as collaboration, and new product launches in the field of the neurological biomarker to remain competitive in the marketplace. For instance, in September 2022, Metabolomics firm Metabolon partnered with the Lee Kong Chian School of Medicine at Nanyang Technological University, Singapore (NTU Singapore) on the identification of biomarkers for a range of health conditions. Metabolon accesses data from an NTU Singapore-led population cohort study to identify biomarkers related to the prevention, diagnosis, and treatment of a range of conditions. Furthermore, in February 2023, C2N Diagnostics, LLC, announced it has received a $15 million program-related investment from GHR Foundation. This financing signifies the foundation’s deep commitment to the company and to reducing the global burden of Alzheimer’s disease through early detection and prevention. Through this funding, the company conducted additional clinical studies to continue building real-world evidence around the use of PrecivityAD and PrecivityAD2, blood tests in clinical care. The investment enables broader market access, expanded medical education, biomarker pipeline development, and infrastructure growth to facilitate global expansion.

Market Coverage

The market number available for – 2022-2030

Base year- 2022

Forecast period- 2023-2030

Segment Covered- 

o By Biomarker Type

o By Application 

o By End User 

Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

Competitive Landscape- including Abbott Laboratories, Bio-Rad Laboratories Inc., Qiagen N.V., Quanterix, Thermo Fisher Scientific Inc., and others.

Key questions addressed by the report

What is the market growth rate?

Which segment and region dominate the market in the base year?

Which segment and region will project the fastest growth in the market?

Who is the leader in the market?

How are players addressing challenges to sustain growth?

Where is the investment opportunity?

Global Neurological Biomarkers Market Report Segment

By Biomarker Type  

  • Imaging Biomarkers
  • Metabolomics Biomarkers
  • Proteomic Biomarkers
  • Genomics Biomarkers

By Application 

  • Alzheimer’s Disease
  • Parkinson’s Disease
  • Multiple Sclerosis
  • Autism Spectrum Disorders
  • Others (stroke, or epilepsy) 

By End User 

  • Hospital 
  • Clinical Diagnostic Centers
  • Research Organizations

Global Neurological Biomarkers Market Report Segment by Region

North America

United States

Canada

Europe

UK

Germany

Italy

Spain

France

Rest of Europe 

Asia-Pacific

China

India

Japan

South Korea

Rest of Asia-Pacific 

Rest of the World

Latin America 

Middle East & Africa


To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/neurological-biomarkers-market